The human rhabdomyosarcoma cell line TE671 has been used extensively to study different aspects of muscle biology. However, its ability to differentiate and form myotubes has not been explored. Here, we examined muscle differentiation when we specifically stopped proliferation of human TE671 (WT-TE671) cells by using 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), an MAPK inhibitor. Our data show that treated cells initiated fusion, and myotube formation and that expression levels of dysferlin and myogenin were increased, whereas those of pax7 were decreased. Treatment of WT-TE671 cells with vitamin D3 alone and cotreatment with U0126 also promoted dysferlin expression. In addition, we knocked out the DYSF gene, which is involved in muscle differentiation, using CRISPR/Cas9 technology in WT-TE671 cells (Dysf-KO TE671). No dysferlin expression was observed before and after U0126 treatment. Although myogenin expression was absent in vehicletreated Dysf-KO TE671 cells, after addition of U0126, myogenin reached levels similar to WT-TE671. This widely available source of human cells appropriately treated with U0126 may represent a useful model to study human muscle physiology in vitro. This dysferlindeficient cell line should allow the study of pathophysiological pathways involved in dysferlin-deficient muscle and constitute a tool for high-throughput screening of therapeutic compounds for patients with dysferlinopathy and other muscle diseases.
INTRODUCTION
Most studies of muscle differentiation in vitro are based on experiments performed in nonhuman cell lines (e.g. C2C12 and L6) or human primary cultures. In 2007, a protocol based on transfection of human telomerase reverse transcriptase and cyclin-dependent kinase 4 allowed the immortalization of human myoblasts from patients (1) . These cells constitute an excellent model to study the pathophysiology of different neuromuscular diseases. However, the number of cell passages, which clearly surpasses that of nonimmortalized myoblasts, is limited. Also, the mutations available of each disease are also limited to those of the patients that kindly give permission to perform the experiments. The use of cell lines is very convenient because they are easy to handle and can be grown almost indefinitely. Moreover, because pathological and nonpathological muscle biopsies are difficult to obtain, using clustered regularly interspaced short palindromic repeats (CRISPRs)/CRISPR-associated protein 9 (Cas9) technology, the mutation of interest can be introduced thereby eliminating the need for myoblasts from patients with specific mutations.
The human rhabdomyosarcoma cell line TE671 (WT-TE671) presents a mutation in the k-RAS gene that leads to upregulated Ras activity. Ras is a key element in the MAPK/ ERK signal transduction pathway, which plays major effector roles in cellular responses such as cell growth, prevention of apoptosis or cell cycle arrest (2) (3) (4) (5) (6) . TE671 cells present a high proliferation potential and are undifferentiated and pleomorphic in shape (7) (8) (9) . In previous publications, it has been shown that TE671 can express increased levels of differentiation markers (e.g. myosin and troponin T) after treatment with cytotoxic drugs such as cisplatinum (DNA crosslinking), etoposide or doxorubicin (both topoisopmerase II inhibitors). However, no myotube-like structures have been observed (10) .
1,4-Diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126) is an MAPK/ERK inhibitor which deactivates MEK 1/2 (3, 4, (11) (12) (13) . Although it has been reported that proliferation of WT-TE671 can be arrested with U0126 (14) , the capacity of these cells to differentiate and form myotubes has not been explored.
Dysferlin is a 230 kDa protein expressed mainly in the sarcolemma and T-tubules of skeletal muscle cells and in peripheral blood monocytes (15) (16) (17) . Mutations in dysferlin gene (DYSF) cause a heterogeneous group of muscular dystrophies named dysferlinopathies (18) (19) (20) . Dysferlin is involved in skeletal muscle repair (21, 22) . In vitro studies demonstrated that dysferlin is expressed at low levels in myoblasts and at high levels in mature myotube, coinciding with the highest expression of myogenin (23, 24) . In dysferlindeficient skeletal muscle cells from dysferlinopathy patients, myoblasts and myotubes in addition to the absence of dysferlin presented a reduced expression of myogenin (25) . Dysferlin-deficient muscle releases increased levels of thrombospondin-1 (TSP-1), which can be crucial in the inflammatory process observed in dysferlinopathies (26, 27) .
Furthermore, it has been reported that vitamin D3 enhances dysferlin expression through a nongenomic pathway involving the MAPK cascade and a genomic pathway through vitamin D receptor binding to the dysferlin promoter (28) .
The CRISPR/Cas9 technology is a powerful tool for gene editing (29) (30) (31) . The two most decisive factors for high CRISPR/Cas9 knock out efficiencies are sufficient nuclear Cas9 delivery to the cell line and the selection of a powerful single guide RNA (sgRNA).
The aim of our study was to assess the utility of WT-TE671 cell line as a widely available source of human cells able to proliferate and differentiate in a way that mimics human primary cultures. Furthermore, the creation of a human dysferlin-deficient cell line using CRISPR/Cas9 editing would be useful to study the pathophysiological processes in muscle from dysferlinopathy patients. This approach could be applied to any muscle disease.
MATERIALS AND METHODS

Rhabdomyosarcoma Cell Line TE671
Human rhabdomyosarcoma cell line TE671 (ECACC no. 85111502) was obtained from American type Culture Collection (Manassas, VA). TE671 were seeded on culture well plates that were coated with gelatin plus laminin. The surface of well plates was incubated with 0.15% gelatin (Sigma-Aldrich, St. Louis, MO) for 30 minutes. We then added 0.01 g/L EHS laminin (Invitrogen, Thermo-Fisher Scientific, Waltham, MA) in L-15 medium (Lonza Group, Ltd., Basel, Switzerland) supplemented with 0.2% NaHCO 3 (Lonza Group) and plates were incubated overnight. Coating medium was removed before plating cells.
TE671 cells were grown in proliferation media (i.e. Dulbecco's modified Eagle medium [DMEM] supplemented with 10% fetal bovine serum [FBS], 2 mM glutamine, 1 mM sodium pyruvate and penicillin-streptomycin, all from Lonza Group), until the culture reached 80%-85% of confluence (humidified, 37 C, 5% CO 2 ). We then performed a treatment based on a two-step cycle. Cells were seeded in proliferation media (day 0), and at day 3 and day 4 the TE671 cells were treated with U0126 (Sigma-Aldrich) in differentiation media (i.e. DMEM supplemented with 2% FBS, 2 mM glutamine and penicillin-streptomycin, all from Lonza Group), adding fresh media each day. At day 5, we changed the culture media adding differentiation media alone. At day 8 we again added U0126 (Sigma-Aldrich) in differentiation media (2% FBS-DMEM). We analyzed sample cells at days 3, 6 and 9. To determine the effect of U0126 on TE671 differentiation, we tested different concentrations of U0126 (10, 20 and 30 mM). Cells treated with an equivalent volume of vehicle (DMSO controls and nontreated cells) were used as control. When vitamin D3 (Sigma-Aldrich) was tested, it was added in each change of medium at 100 nM.
Immunocytochemistry
Cells cultured on glass coverslips were fixed for 10 minutes in 4% paraformaldehyde and permeabilized in blocking solution containing 0.1% Triton-X for 45 minutes. The samples were incubated overnight with monoclonal antibodies antidysferlin (Novocastra, Leica, Wetzlar, Germany) and antimyosin heavy chain (MyCH) (hybridome clone MF20, IA) followed by 1 hour with goat antimouse IgG (Vector Laboratories, Burlingame, CA). Nuclei were stained with Hoescht 33342 (Invitrogen, Thermo-Fisher Scientific) at 1 mg/mL. Coverslips were then mounted in a glycerol medium containing polyvinyl alcohol (Fluoprep, BioMerieux, Durham, CA). As a negative control, samples were processed without a primary antibody but using the same secondary antibody. Images were taken using a BX51 microscope coupled to a DP72 camera (Olympus, Tokyo, Japan).
Western Blot
Cell samples corresponding to each day analyzed (i.e. days 3, 6 and 9) were scraped from the culture plate. Protein extraction was performed with RIPA buffer (Sigma-Aldrich). Ten micrograms of protein was loaded in each well. Samples were subjected to electrophoresis on 8% sodium dodecyl sulphate (SDS)-polyacrylamide gel and transferred to nitrocellulose transfer membranes. To test transfer conditions, we stained total protein in the nitrocellulose membrane using RE-VERT Total Protein Stain (LI-COR, Lincoln, NE). Unspecific binding sites on the blots were blocked by incubation for 1 hour in Odyssey Blocking Buffer (LI-COR) diluted 1:1 in phosphate-buffered saline (PBS). The blots were incubated for 2 hours with the primary mouse monoclonal antibodies antidysferlin (Novocastra) and antimyogenin (5FD clone) (Santa Cruz Biotechnology, Dallas, TX). To normalize the results, mouse anti-b-actin (Sigma) added simultaneously with the primary antibody or staining of the nitrocellulose membrane with REVERT (LI-COR) were used. The secondary antibody for antidysferlin was a goat antimouse labeled with IR-Dye 680. When antimyogenin antibody was used as a primary antibody, biotin-labeled horse antimouse was used as the secondary antibody. Secondary antibodies were incubated for 1 hour. Membranes incubated with biotinylated secondary antibodies were washed and incubated for 1 hour with IRDye-800-labeled streptavidin (LI-COR). After extensive washing, the immunoreactive bands were visualized using the Odyssey Infrared Imaging System (LI-COR). The WT-TE671 vehicle-treated samples were used as reference values and assigned 100% of dysferlin expression using b-actin as a normalizer.
RNA Extraction and Real-Time PCR
Total RNA from treated and nontreated cell cultures at days 3, 6 and 9 was extracted using Trizol (Life Technologies, Carlsbad, CA) and 0.5 mg of total RNA were reverse transcribed into cDNA using the high capacity cDNA RT-kit (Life Technologies). Quantification of Pax7 and GAPDH (used as internal standard) transcripts was performed using TaqMan Universal Master Mix technology (Life Technologies). Quantitative PCR as performed in a total reaction volume of 20 mL per well. The primers used for real-time PCR were Pax7 (Hs00242962_m1) and GAPDH (Hs9999905_m1) (Applied Biosystems, Foster City, CA). The comparative Ct method (DCt) for relative quantification of gene expression was used.
CRISPR/Cas9 Methodology TE671 cells were transfected using Nucleofector II system (Lonza Group) with pSpCas9(BB)-2A-green fluorescence protein (GFP) (PX458) that was a gift from Feng Zhang (Addgene plasmid # 48138) (32) , containing the sgRNA sequence 5 0 AGATGTACTACACACACCGA3 0 against exon 29 of DYSF. The sgRNA was designed using specific software (crispr.mit.edu by F. Zhang). In addition, we checked for the presence of possible off-targets recognized by the sgRNA using the software Breaking Cas (33) (Supplementary Data Table S1). 2.5 Â 10 6 TE671 cells were transfected with 3 mg of plasmid DNA, using a Nucleofector II device (Lonza Group). Twenty-four hours after transfection, GFP-positive surviving cells were sorted using a FACSAria Sorter (BD Biosciences, Franklin Lakes, NJ). TE671 cells DNA extraction of was performed using DNeasy Blood and tissue kit (Qiagen, Hilden, Germany). Following clonal expansion, DYSF gene was sequenced for the detection of mutations in exon 29 and protein extracts were immunoblotted to confirm the absence of dysferlin.
T7 Endonuclease Assay
To detect unknown mutations created using CRISPR/ Cas9 methodology, we used a mismatch-specific DNA endonuclease to scan for that. We used IDT Surveyor Mutation Detection kit (Integrated DNA Technologies, Coralville, IA), which contains a DNA endonuclease that cuts both strands of a DNA heteroduplex on the 3 0 side of the mismatch site. We performed 2 PCR reactions with the following primers: 5 0 -TGGAAGTGGGAAGATGAGGAATG-3 0 and 5 0 -GTGTGATCTGTGAGCACCTCCAG-3 0 , using the DNA from WT-TE671 cells and the Dysf-KO TE671 cells. After that, PCRs were mix 1:1 and hybridized to form heteroduplexes. Finally, the duplexes were treated with the Surveyor Nuclease and DNA fragments were analyzed by agarose gel electrophoresis.
Cloning of Transfected Cells
Cells were counted and a limit dilution was performed to obtain a single cell per well culture in a 96-well plate. We obtained 98 clones from the initial Dysf-KO TE671 culture and 10 were sequenced.
Sanger Sequencing
We also sequenced DYSF exon 29 from WT-TE671 and Dysf-KO cells. Total genomic DNA from the cells was employed as a template for PCR amplification with the primers of the T7 endonuclease assay. Amplified products were purified using PCR purification kit (Danagen, Barcelona, Spain) and were analyzed by direct forward and reverse sequencing, with a DNA sequencing kit (Big Dye 3.1 Applied Biosystems) on an automatic sequencer (ABI Prism 3100 Avant, Applied Biosystems).
Thrombospondin-1 Enzyme Linked Immunosorbent Assay (ELISA)
Cell cultures from WT-and Dysf-KO TE671 were seeded at 2500 cells/cm 2 . After 6 days in proliferation media, we removed the medium and added 1 mL of basal DMEM (Lonza Group) medium for 24 hours. Then, culture supernatants were concentrated using Amicon Ultra Centrifugal Filters 100 kb (Merck Millipore, Darmstadt, Germany). TSP-1, present in the culture media of TE671 cells and Dysf-KO TE671 cells, was detected with human TSP-1 Immunoassay (QuantiKine ELISA, R&D Systems, Minneapolis, MN), following the manufacturer's instructions. All samples (n ¼ 6) were analyzed in triplicate. The limit of detection was 0.355 ng/mL.
Membrane Repair Assay
Both WT-and Dysf-KO TE671 cells were grown until confluence. SDS is an anionic surfactant that causes the leakage of intracellular components due to ability to affect membranes (34) . The assay was performed as recently described in human muscle primary cultures (35) . Membrane injury was induced by detergent treatment as follows: After the cell cultures were washed with Hank's Balanced Salt Solution (HBSS) (Lonza Group), the injury solution (HBSS with 0.25 mM SDS [Sigma-Aldrich]) was applied for 2 minutes. Following exposure to injury solution, cells were washed in HBSS and then incubated in recovery solution consisting of proliferation media for 90 seconds and 10 minutes. The injury and recovery steps were performed at 37 C. Cells with injured permeable membranes were identified by exposure to propidium iodide ([PI]; Sigma-Aldrich) (200 mg/mL in HBSS). In the presence of an injured cellular membrane, this normally impermeable molecule enters the cell and penetrates into the nucleus where it intercalates with DNA and fluoresces. After 2 minutes of exposure to the dye, cells were washed with HBSS and fixed with 4% of paraformaldehyde in PBS. In each experimental condition, we counted the total number of nuclei and the PIpositive nuclei. We analyzed a total of 3600 nuclei using Fiji software (36) .
Statistical Analysis
The Student t-test was used for statistical comparisons between the data obtained in treated and nontreated cultures. Multiple comparisons were analyzed using a two-way ANOVA test. GraphPad Prism 5.0 software was used (La Jolla, CA).
RESULTS
U0126-Treated Cells Show Increased Differentiation
U0126-treated TE671 cells presented prolonged survival and enrolment into the differentiation state. The two-step cycle used to treat the cell cultures with U0126 proved to be more effective than continuous exposure to the drug, which produced premature cell death without differentiation of the cells. From all the U0126 concentrations tested (10, 20 and 30 mM), we chose 20 mM as the optimal concentration to obtain myotubes. Furthermore, at 20 mM, U0126 dysferlin expression was higher at all the days analyzed compared with the other concentrations tested (data not shown).
U0126-treated TE671 cells are able to form myotubes indicating in vitro muscle cell differentiation. We designed our experiments to analyze the presence of differentiation markers by immunocytochemistry and Western blot (WB) (Fig. 1A) . MyHC was expressed in differentiated TE671 cells after U0126 treatment. The expression of dysferlin was also increased with the treatment. WT-TE671 cells treated with DMSO (vehicle) showed no expression of either MyHC or dysferlin (Fig. 1B) . Myogenin was also analyzed as a muscle differentiation marker. After U0126 treatment, myogenin levels increased ( Fig. 2A) , reaching significant differences at day 3 (p < 0.05) (Fig. 2B) . Analysis of Pax7 mRNA was performed by real-time PCR. We observed a decreased expression of Pax7 mRNA at day 3 (Fig. 2C) . These results correlate with myogenin expression, at day 3 in vehicle-treated cells low levels of myogenin were detected by WB and Pax7 expression was high (p < 0.05). After more than 3 days in culture, cells are very confluent and the levels of Pax7 drop dramatically in both nontreated and treated cells. After U0126 treatment, levels of myogenin increased, levels of Pax7 were reduced and dysferlin analysis by WB showed significantly higher levels at day 9 ( Fig. 2D, E) . We also analyzed the effects of vitamin D3 in U0126-treated cultured cells. At all days analyzed, dysferlin reached maximum levels in vitamin D3-treated cells (both in nontreated and U0126-treated cultures) (Fig. 2C, D) .
Dysf-KO TE671 Cells by CRISPR/Cas9
We designed a sgRNA against exon 29 of DYSF. We used a pSpCas9(BB)-2A-GFP (PX458) plasmid (Addgene Quantification of percentage of dysferlin expression showed a statistically significant increased expression of U0126-treated versus -untreated TE671 cells at day 9. Vitamin D3-treated cultures and combined treatments of vitamin D3 and U0126 showed higher levels of dysferlin than untreated cultures. *p < 0.05, **p < 0.01, ***p < 0.001. plasmid #48138), which encodes for a Cas9 nuclease with the ability to cut double-stranded DNA. After nucleofector transfection the mortality was around 97.5%, and we were only able to recover 0.12% GFP-positive transfected cells. We expanded the surviving cells and checked for the presence of mutations in DYSF using a T7 endonuclease assay (Fig. 3) . In lane 4 corresponding to the heteroduplex WT þ KO, we can see the product of the endonuclease digestion, showing 2 cleaved products of 361 and 255 bp. In lane 3, corresponding to the KO homoduplex, we also observed the cleaved products that were not visible in the WT homoduplex (lane 2), in PCR amplicons from Dysf-KO (lane 5) or in WT (lane 6) TE671 cells. We isolated 98 clones from our Dysf-KO TE671 population and sequenced the region targeted by the sgRNA in 10 of them. We found the same change in all of them (Fig. 3C) . The 2 alleles in Dysf-KO TE671 did not bear the same changes, and for this reason we observed 2 cleaved products in the T7 surveyor assay. The changes observed in exon 29 of DYSF gene were: c.3103_3112del, c.3112dup, c.3147T>G and c.3150C>G (reference sequence NM_3494.3) (Fig. 3) . 
Dysf-KO TE671 Cells Do Not Express Dysferlin or Myogenin
In Dysf-KO TE671, dysferlin expression was completely absent in both U0126-treated and vehicle-treated cell cultures (Fig. 4A) . Levels of dysferlin in Dysf-KO TE671 were very low in both U0126-treated and -untreated cultures (Fig. 4B) . Myogenin was reduced in Dysf-KO TE671 cells, whereas in U0126-treated cells myogenin expression increased reaching significant levels at day 3 (p < 0.05) (Fig. 4C, D) .
Expression of TSP-1
We previously observed that dysferlin-deficient muscle cells from dysferlinopathy patients showed a higher chemotactic activity due to an increased release of TSP-1 (26) . For this reason, we evaluated the expression of TSP-1 in WT-TE671 cell cultures compared to Dysf-KO cell cultures. TSP-1 concentration in WT-TE671 cell cultures supernatant was 10.5 6 2.8 ng/mL and in Dysf-KO TE671 was 126.6 6 40.8 ng/mL. These differences were statistically significant (p < 0.05).
Repair Assay and Quantitation of Muscle Injury
It has been reported that dysferlin has a prominent role in membrane repair after injury. We used a 2-minute exposure to mild concentrations of SDS detergent followed by varying times of recovery (90 seconds and 10 minutes) and then 2 minutes of incubation in PI, a marker of persisting membrane leakage indicated by nuclear uptake and fluorescence. Representative images of PI-positive nuclei are shown in Figure 5 . Dysf-KO TE671 cells failed to show a degree of recovery of PI exclusion at 10 minutes after injury equivalent to WT cells (Fig. 5 ).
DISCUSSION
In this paper, we have designed a step-by-step protocol to differentiate the widely used human cell line TE671 into mature myotubes as an in vitro model to study muscle pathology. We have also created a dysferlin-deficient TE671 cell line, using CRISPR/Cas9 methodology (32) . Mouse and rat muscle cell models (e.g. C2C12 or L6) cannot completely replace research done on human cells. As primary cell cultures are not always readily available and their preparation is timeconsuming, a well-characterized human cell line, such as TE671, could provide an alternative source of human muscle cells for diagnosis, drug screening and/or basic research.
Because TE671 presents upregulated Ras activity, we were interested in characterizing the effect of U0126, an MAPK blocker, on TE671 cells differentiation into myotubes. It has also been shown that U0126 has toxic effects on cancer cells (13, 14, 37, 38) . To minimize these effects, we designed experiments that allowed us to find the minimal toxic concentration and treatment regime necessary to stop proliferation and keep cells alive in a differentiated state for long periods of time. With this goal in mind, we designed a "two-step" drug treatment that avoided a toxic effect by U0126, thereby prolonging cell survival. We established the optimal drug concentration that allowed cell survival and the formation of myotubes. After treatment with 20 mM U0126, we observed myotube formation in TE671 cultures and increased expression of dysferlin and differentiation markers such as myogenin (39) , which are expressed at low levels in nontreated TE671 cell line. We observed that Pax7 is reduced when myogenin is expressed. In fact, it has been described that in differentiating cultures of myoblasts, Pax7 is coexpressed with MyoD at early stages of differentiation but is not present in cells expressing myogenin (34) . These data show that treatment with U0126 promotes TE671 differentiation in a pattern similar to nonpathological human muscle primary cultures (24, 25, 40) . As previously described (28) , vitamin D3 has an important effect on dysferlin expression. It has been demonstrated that transcriptional activity of dysferlin can be modulated by vitamin D3 and this process is mediated by 2 pathways: 1) an MAPK/ERK cascade that could be inhibited by U0126 (41) and 2) a direct genome effect by binding to the specific D3-type VDRE consensus sequence present in the DYSF promoter (28) .
In the cell cultures treated with vitamin D3 (with and without U0126), dysferlin expression increased significantly at all time points, indicating the involvement of the genomic pathway of vitamin D3 in dysferlin expression since the MAPK/ERK pathway was blocked by UO126.
Importantly, our Dysf-KO TE671 in vitro model also recapitulated some of the features observed in human primary skeletal muscle cultures from dysferlinopathy patients, such as reduced myogenin expression (25) , increased TSP-1 expression (26) and altered sarcolemmal repair (21) . The Dysf-KO TE671 could be used to unravel the molecular mechanisms involved in the role of dysferlin in muscle differentiation or in muscular chemotaxis toward inflammatory cells. A possible caveat of this model might be that MAPK/ERK inhibition takes place downstream of pathologically activated Ras and, consequently, activated MAP3K could mediate a crosstalk with other signaling pathways (42) (43) (44) (45) . Regarding the membrane repair experiments, this model could be used to screen compounds that speed up the membrane resealing process with applications not only in patients with muscle diseases but also to treat muscle lesions in professional athletes who could shorten their return to competition.
In conclusion, our findings demonstrate the usefulness of the human TE671 cell line as an in vitro model to study human muscle physiology and pathology. Furthermore, these human in vitro models could also be used to develop drug screening assays for muscle cell pathways that are impaired in muscle diseases.
